Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Globenewswire
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like VTAK with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on VTAK
About VTAK
Catheter Precision, Inc. is a medical device company bringing solutions to market to improve the treatment of cardiac arrhythmias. The Company is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The Company's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. It is developing technology for the treatment of acute decompensated heart failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Catheter Precision Implements LockeT at Ireland's Largest EP Center
- Global Expansion Milestone: Catheter Precision successfully implements LockeT at Mater Private Hospital in Ireland, marking a significant advancement in the company's global expansion strategy while enhancing procedural safety and efficiency in cardiac care.
- Key Partnership: As Ireland's largest electrophysiology center performing over 1,000 procedures annually, Mater Private's adoption of LockeT will significantly enhance innovation in arrhythmia treatment.
- Rapid Training and Adoption: The chief nurse trained 52 staff members in just two days, showcasing LockeT's intuitive design and operational efficiency, which ensures swift adoption of the device.
- Market Validation: The European Sales Manager highlighted that Mater Private's multi-year commitment to LockeT validates the technology's value and strengthens Catheter Precision's position in the global electrophysiology market.
Continue Reading
Catheter Precision Launches LockeT Device in Switzerland with Positive Clinical Outcomes
- Successful Product Launch: Catheter Precision has successfully launched its LockeT suture retention device in Switzerland, with the first clinical cases performed at Spitalzentrum Biel yielding excellent procedural outcomes and positive feedback from clinical and nursing teams, marking a significant technological advancement in the cardiac electrophysiology market.
- Strategic Distribution Agreement: The partnership with FuMedica AG, a leading Swiss medical device distributor, enables rapid introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision's footprint in the European market.
- Cost Efficiency Improvement: The intuitive design of the LockeT device not only reduces groin management costs but also supports same-day discharge, enhancing the overall patient experience and demonstrating its potential application in cardiac interventional procedures.
- Global Market Expansion: With over 10,000 LockeTs shipped globally to date, Catheter Precision is actively expanding its business in the rapidly growing cardiac electrophysiology market, working diligently with partners to improve patient treatment outcomes.
Continue Reading